ES2663242T3 - Productos génicos expresados de forma diferencial en tumores y su utilización - Google Patents
Productos génicos expresados de forma diferencial en tumores y su utilización Download PDFInfo
- Publication number
- ES2663242T3 ES2663242T3 ES10011193T ES10011193T ES2663242T3 ES 2663242 T3 ES2663242 T3 ES 2663242T3 ES 10011193 T ES10011193 T ES 10011193T ES 10011193 T ES10011193 T ES 10011193T ES 2663242 T3 ES2663242 T3 ES 2663242T3
- Authority
- ES
- Spain
- Prior art keywords
- nucleic acid
- tumor
- associated antigen
- tumor associated
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 8
- 239000000427 antigen Substances 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 108020004707 nucleic acids Proteins 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10341812A DE10341812A1 (de) | 2003-09-10 | 2003-09-10 | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2663242T3 true ES2663242T3 (es) | 2018-04-11 |
Family
ID=34258548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10011193T Expired - Lifetime ES2663242T3 (es) | 2003-09-10 | 2004-09-10 | Productos génicos expresados de forma diferencial en tumores y su utilización |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8765389B2 (enExample) |
| EP (7) | EP3095791B1 (enExample) |
| JP (3) | JP5007123B2 (enExample) |
| AU (1) | AU2004272270B2 (enExample) |
| CA (1) | CA2538528C (enExample) |
| DE (1) | DE10341812A1 (enExample) |
| ES (1) | ES2663242T3 (enExample) |
| WO (1) | WO2005026205A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1795596A1 (en) * | 2005-12-08 | 2007-06-13 | Ganymed Pharmaceuticals AG | Composition and methods for therapy and diagnosis of cancer |
| EP1911851A1 (en) * | 2006-10-12 | 2008-04-16 | Ganymed Pharmaceuticals AG | Compositions and methods for therapy and diagnosis of cancer and cancer metastasis |
| EP2060583A1 (en) * | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| EP2108701A1 (en) * | 2008-04-10 | 2009-10-14 | Ganymed Pharmaceuticals AG | Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing |
| JP5565723B2 (ja) * | 2009-04-07 | 2014-08-06 | 学校法人北里研究所 | 抗ｄｃｄモノクローナル抗体 |
| EP2618835B1 (en) | 2010-09-20 | 2017-07-05 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
| WO2013164787A1 (en) | 2012-05-02 | 2013-11-07 | Helse Stavanger As | Assay methods for diagnosing and monitoring cancer |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| WO2015140567A1 (en) * | 2014-03-21 | 2015-09-24 | Immunocore Limited | Tumor associated antigens derived from traip |
| MX2018007204A (es) | 2015-12-16 | 2018-12-11 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno. |
| AU2018348165B2 (en) | 2017-10-10 | 2025-09-04 | Seattle Project Corp. | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| US11308700B2 (en) | 2020-04-06 | 2022-04-19 | Saudi Arabian Oil Company | Augmented reality visualization of underground pipelines using geospatial databases and KM markers |
| WO2021251842A1 (en) * | 2020-06-08 | 2021-12-16 | Qatar Foundation For Education, Science And Community Development | Targeting of lactate dehydrogenase c, methods of preparing same, and methods of using same in combination with anti-cancer treatments |
| IL309952A (en) | 2021-07-29 | 2024-03-01 | BioNTech SE | Compositions and methods for treating melanoma |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8192987A (en) * | 1986-12-01 | 1988-06-16 | Northwestern University | Human ldh-c4 cdna sequences encoding antigenic regions |
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| WO1999033963A1 (en) * | 1997-12-31 | 1999-07-08 | Chiron Corporation | Metastatic cancer regulated gene |
| EP1053323A2 (en) * | 1998-02-12 | 2000-11-22 | Incyte Pharmaceuticals, Inc. | Human receptor proteins |
| US6262333B1 (en) * | 1998-06-10 | 2001-07-17 | Bayer Corporation | Human genes and gene expression products |
| WO2000012702A2 (en) * | 1998-08-31 | 2000-03-09 | Bayer Corporation | Human genes differentially expressed in colorectal cancer |
| AU2387900A (en) * | 1998-12-23 | 2000-07-12 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| DE19936563A1 (de) | 1999-08-04 | 2001-02-08 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
| AU7058000A (en) * | 1999-08-13 | 2001-03-13 | Human Genome Sciences, Inc. | 13 human colon and colon cancer associated proteins |
| CA2384713A1 (en) * | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2001283012A1 (en) * | 2000-07-28 | 2002-02-13 | Incyte Genomics, Inc. | Protein phosphatases |
| US20020160382A1 (en) * | 2000-10-11 | 2002-10-31 | Lasek Amy W. | Genes expressed in colon cancer |
| WO2002062946A2 (en) * | 2000-12-08 | 2002-08-15 | Duke University | Identification of novel ms4a gene family members expressed by hematopoietic cells |
| AU2002255478A1 (en) * | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| EP1222928A3 (en) | 2001-01-16 | 2003-11-05 | Universität Zürich Institut für Medizinische Virologie | Pharmaceutical compositions for treating or preventing cancer, especially melanoma |
| AU2002307154A1 (en) * | 2001-04-06 | 2002-10-21 | Origene Technologies, Inc | Prostate cancer expression profiles |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| JP2006516089A (ja) * | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| WO2005052182A2 (en) * | 2003-11-26 | 2005-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method of analyzing plasma membrane protein content of cells |
-
2003
- 2003-09-10 DE DE10341812A patent/DE10341812A1/de not_active Withdrawn
-
2004
- 2004-09-10 WO PCT/EP2004/010164 patent/WO2005026205A2/de not_active Ceased
- 2004-09-10 EP EP16176546.6A patent/EP3095791B1/de not_active Expired - Lifetime
- 2004-09-10 CA CA2538528A patent/CA2538528C/en not_active Expired - Lifetime
- 2004-09-10 AU AU2004272270A patent/AU2004272270B2/en not_active Expired
- 2004-09-10 US US10/570,957 patent/US8765389B2/en active Active
- 2004-09-10 EP EP10011193.9A patent/EP2327721B1/de not_active Expired - Lifetime
- 2004-09-10 EP EP04765088A patent/EP1664103A2/de not_active Withdrawn
- 2004-09-10 EP EP10011191A patent/EP2336157A3/de not_active Withdrawn
- 2004-09-10 EP EP10011192A patent/EP2314613A3/de not_active Withdrawn
- 2004-09-10 ES ES10011193T patent/ES2663242T3/es not_active Expired - Lifetime
- 2004-09-10 JP JP2006525779A patent/JP5007123B2/ja not_active Expired - Lifetime
- 2004-09-10 EP EP10011190A patent/EP2336156A3/de not_active Withdrawn
- 2004-09-10 EP EP10011194A patent/EP2322544A3/de not_active Withdrawn
-
2011
- 2011-09-20 JP JP2011205112A patent/JP2012050441A/ja active Pending
-
2012
- 2012-07-10 JP JP2012154564A patent/JP5711698B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US8765389B2 (en) | 2014-07-01 |
| EP2336156A2 (de) | 2011-06-22 |
| CA2538528A1 (en) | 2005-03-24 |
| EP2327721B1 (de) | 2017-12-27 |
| WO2005026205A3 (de) | 2005-07-07 |
| EP2336157A3 (de) | 2011-11-16 |
| EP2336157A2 (de) | 2011-06-22 |
| EP2322544A2 (de) | 2011-05-18 |
| DE10341812A1 (de) | 2005-04-07 |
| AU2004272270A1 (en) | 2005-03-24 |
| EP2327721A2 (de) | 2011-06-01 |
| JP5711698B2 (ja) | 2015-05-07 |
| EP2314613A2 (de) | 2011-04-27 |
| EP2336156A3 (de) | 2011-11-16 |
| US20100203040A1 (en) | 2010-08-12 |
| EP2327721A3 (de) | 2011-09-21 |
| CA2538528C (en) | 2020-03-10 |
| EP3095791B1 (de) | 2020-06-10 |
| AU2004272270B2 (en) | 2011-07-21 |
| WO2005026205A2 (de) | 2005-03-24 |
| EP2314613A3 (de) | 2011-11-16 |
| JP2007526759A (ja) | 2007-09-20 |
| JP2013009673A (ja) | 2013-01-17 |
| EP3095791A1 (de) | 2016-11-23 |
| EP1664103A2 (de) | 2006-06-07 |
| JP5007123B2 (ja) | 2012-08-22 |
| EP2322544A3 (de) | 2011-11-16 |
| JP2012050441A (ja) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2663242T3 (es) | Productos génicos expresados de forma diferencial en tumores y su utilización | |
| AR111207A1 (es) | Anticuerpos anti-lag3 | |
| AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
| ES2542853T3 (es) | Método para tratar miastenia grave | |
| AR110101A1 (es) | Miembros de unión (2) | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| DE69940671D1 (de) | Mage-a3 polypeptide die durch hla-klasse ii molekule präsentiert werden | |
| ES2675375T3 (es) | Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer | |
| ATE432983T1 (de) | Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden | |
| AR047347A1 (es) | Miembros de la familia cry9 de bacillus | |
| AR036160A1 (es) | Regulacion de las vias metabolicas lipidicas en las plantas, mediante transgenesis con sentido o antisentido de factores de transcripcion hap2, hap5 y hap3/lec1 | |
| RU2012129208A (ru) | Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения | |
| RU2007136026A (ru) | Варианты ил-21 | |
| AR093186A1 (es) | Proteinas de union al antigeno cd27l | |
| DE502005009602D1 (de) | Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie | |
| CL2019003409A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| MX2022005704A (es) | Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b. | |
| EA201070108A1 (ru) | Cd44 сплайс-варианты в нейродегенеративных заболеваниях | |
| DK1481990T3 (da) | A33-beslægtede antigener og deres farmakologiske anvendelser | |
| BRPI0507579A (pt) | molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea | |
| US20170183660A1 (en) | Aptamer targeting mage-a3 peptide and uses thereof | |
| NO20053112L (no) | Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike. | |
| PE20021098A1 (es) | ANTICUERPOS ESPECIFICOS DE CD44v6 | |
| EP1536006A4 (en) | CANCER-ANIMALS AND THEIR USE |